Galen Health
DELIBERATELY THIN RECORD. Galen Health occupies a segment nothing else in this index covers, which is why it is here, but almost nothing about the company is publicly verifiable and most axes below are Not Rated for that reason rather than because the posture is poor. Galen sells what it calls AI teammates for tumor boards. The multidisciplinary tumor board is the forum where a cancer patient's case is presented to surgeons, medical and radiation oncologists, pathologists and radiologists together, and a treatment recommendation is agreed. Preparing those cases is heavy manual work and the meetings themselves are time constrained. Galen addresses the whole cycle: preparing the case presentation beforehand, identifying candidate clinical trials, retrieving patient information and insights live during the meeting, and maintaining a knowledge base of the care decisions the board reaches so that past discussions can inform later ones. The company positions it as a single layer unifying oncology workflows across multiple hospitals and clinics. That combination is genuinely distinctive. This index already covers clinical trial matching as its own category and chart summarisation as this one, but nothing else addresses the tumor board as a workflow, and no other product reviewed here operates inside a live multidisciplinary meeting rather than at an individual clinician's desk. What is missing is everything a buyer would use to evaluate it. No customer is named, no funding is disclosed, no deployment is documented, no model or accuracy information exists, and the efficiency claims, hours saved weekly and millions in hospital cost reduction, carry no substantiation. The company describes itself as trusted by leading cancer centres without naming any. Its compliance language is HIPAA ready rather than HIPAA compliant, a distinction discussed on the relevant axis. Treat this record as a placeholder documenting a real and uncovered segment, to be refreshed when the company publishes more.
Capability Axes
The product is AI agents, described by the company as teammates, performing the work themselves rather than presenting someone else's output. Case preparation, trial identification, live retrieval during a meeting and maintenance of a decision knowledge base are all generative and retrieval tasks, and there is no underlying platform, system of record or services business the AI is attached to. Graded on what the product is; note that the rest of this record is thin and a later refresh may revise this if the company turns out to be assembling third party components.
No oversight mechanism was located: no confidence signal, no threshold, no verification step, no statement of what a clinician must check. Not Rated reflects absent retrieval. The gap deserves naming even though it does not change the grade, because the setting is unusually consequential. A tumor board is where a cancer treatment recommendation is agreed by a group, and this product supplies generated case presentations beforehand and retrieved insights live during that discussion. Content entering a group decision carries a specific risk that content read by one clinician does not: no individual owns verifying it, and an error can be absorbed into a consensus nobody separately checked. Ask what the board is expected to verify and who is accountable for it.
Nothing was located. No model or model family named, no accuracy figure of any kind, no methodology, no evaluation, no model card, and no description of how case preparations or trial matches are produced or verified. Not Rated records that the evidence was not retrieved rather than that the posture is poor.
Claims exist and none of them is verifiable. The company states it is trusted by leading cancer centres without naming one, and asserts hours saved weekly and hospital cost reduction in the millions with no baseline, denominator, method or customer attached. No named deployment, no case study, no funding disclosure and no independent evaluation was located. Graded C rather than Not Rated because deployment and benefit are asserted; nothing supports either.
No retention period, training use statement or de identification posture was located. Not Rated reflects absent retrieval. One product feature makes the question sharper than usual and should be raised directly: the platform maintains a knowledge base of the care decisions a tumor board reaches, so it accumulates a longitudinal store of clinical reasoning and treatment choices across patients and institutions. Establish who owns that store, whether it is shared across customers, and what happens to it if the relationship ends.
The company describes itself as HIPAA READY rather than HIPAA compliant, and the distinction is worth holding onto. Ready is not a defined term and asserts capability rather than a state: it typically means the software could be operated compliantly given the right configuration and agreements, which places the obligation on the customer. Compliant, with a business associate agreement in place, is a commitment the vendor makes. This index already tracks hedged compliance language such as HIPAA compliant infrastructure and SOC 2 aligned, and HIPAA ready belongs on the same watchlist. Graded C rather than Not Rated because a claim was located and it is a weak one. Ask whether a BAA is offered and executed as standard.
No SOC 2, HITRUST, ISO 27001 or other attestation was located, and no trust centre or security page was found. Not Rated reflects absent retrieval.
No FDA clearance, device authorisation or regulatory pathway statement was located. Not Rated reflects absent retrieval. The scoping question is live and unaddressed: preparing a case for a treatment decision forum and surfacing trial options during it sits close to the boundary the software as a medical device analysis addresses, and the company says nothing about where it believes it falls.
No governance framework, fairness statement, subgroup performance disclosure or responsible AI documentation was located. Not Rated reflects absent retrieval. Worth noting for a refresh: clinical trial matching is a function where eligibility criteria and access patterns are known to produce uneven representation, and a product that surfaces trial options into a treatment discussion inherits that question whether or not it addresses it.
No EHR vendor, integration mechanism, standard or data source is named anywhere. The company describes unifying oncology workflows across multiple hospitals and clinics with a single layer, which implies multi site data access, but nothing describes how records reach the product. Not Rated reflects absent retrieval, and this is the first thing to establish in any evaluation, since a tumor board product that cannot reach the source records automatically is a meeting tool rather than a case preparation tool.
No hosting model, cloud provider, region, residency commitment or customer hosted option was located. Not Rated reflects absent retrieval.
No price, tier or pricing mechanism was located. Not Rated is the house convention for absent pricing rather than a low grade. The only commercial statement available is a claim that the product cuts hospital costs by millions, which describes asserted value rather than what it charges.
Narrow by design and the narrowness is the point. This is an oncology product addressing one specific forum, the multidisciplinary tumor board, and it covers that forum end to end: preparation before the meeting, retrieval and insight during it, trial identification alongside it, and a decision knowledge base after it. It is positioned to span multiple hospitals and clinics under one layer, which matters because tumor boards are frequently run across sites. Graded B rather than higher because no tumour type, staging system, guideline set or other instrument level behaviour was located, and no evidence establishes the product working in any named cancer centre.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published
|
Undisclosed. | Not published, and the compliance language is HIPAA ready rather than HIPAA compliant. Ask whether a BAA is offered and executed as standard before anything else. | Not published | Vendor Published |
No price, tier or pricing mechanism was located, so commercial transparency is Not Rated per the house convention rather than graded down. The only commercial statement available is an unsubstantiated claim that the product cuts hospital costs by millions. This is a thin record and the diligence list is correspondingly basic. Establish who the named customers are and speak to one, since the company claims leading cancer centres without naming any. Establish how records reach the product, because a tumor board tool that cannot pull from the source systems automatically is a meeting aid rather than a preparation engine and is worth a fraction of the price. Establish whether a business associate agreement is executed as standard, given the HIPAA ready phrasing. And establish ownership of the care decision knowledge base the product accumulates, including whether it is shared across customers and what happens to it at termination, since that store is arguably the most valuable asset the relationship creates and the contract should say who holds it.